Amoéba est membre de Lyonbiopôle

General information

38 avenue des Frères Montgolfier


Incorporated in: 2010/07/21

Number of employees: 40

More information


Main activity

Based in Lyon, France, AMOEBA develops a biological biocide capable of eliminating waterborne bacterial risk (legionella, pseudomonas, listeria, etc.). This entirely natural solution appears to be an alternative to the chemical treatments traditionally used in industry. AMOEBA continues with its regulatory procedures so as to launch a request for provisional MA in the first half of 2016 for all European countries as soon as ANSES (French Agency for Food, Environmental and Occupational Health & Safety) has validated AMOEBA's solution for application in air-cooled towers. In a worldwide market of chemical biocides estimated to be worth 21 bn€, AMOEBA is today concentrating on the segment of industrial air-cooled towers (ACT) estimated at 1.7 bn€. Its disruptive technology complies with new regulations in terms of environmental chemical emissions. AMOEBA is quoted on compartment C of the Euronext Paris stock exchange and joined the CAC Small index on 21 September last.


Public funding obtained: CREALYS 30K€ Rhone alpes region 30K€ French ministry 40K€  

Stock exchange listing: Euronext paris, 10 july 2015


Strategic area of application
Medical Technologies

Application market

Therapeutics, Pharma or Biotech